291 related articles for article (PubMed ID: 36871413)
1. Urine titin as a novel biomarker for Duchenne muscular dystrophy.
Ishii MN; Nakashima M; Kamiguchi H; Zach N; Kuboki R; Baba R; Hirakawa T; Suzuki K; Quinton M
Neuromuscul Disord; 2023 Apr; 33(4):302-308. PubMed ID: 36871413
[TBL] [Abstract][Full Text] [Related]
2. Dramatic elevation in urinary amino terminal titin fragment excretion quantified by immunoassay in Duchenne muscular dystrophy patients and in dystrophin deficient rodents.
Robertson AS; Majchrzak MJ; Smith CM; Gagnon RC; Devidze N; Banks GB; Little SC; Nabbie F; Bounous DI; DiPiero J; Jacobsen LK; Bristow LJ; Ahlijanian MK; Stimpson SA
Neuromuscul Disord; 2017 Jul; 27(7):635-645. PubMed ID: 28554556
[TBL] [Abstract][Full Text] [Related]
3. A sandwich ELISA kit reveals marked elevation of titin N-terminal fragment levels in the urine of mdx mice.
Shirakawa T; Ikushima A; Maruyama N; Nambu Y; Awano H; Osawa K; Nirasawa K; Negishi Y; Nishio H; Fukushima S; Matsuo M
Animal Model Exp Med; 2022 Feb; 5(1):48-55. PubMed ID: 35229992
[TBL] [Abstract][Full Text] [Related]
4. Proteomics profiling of urine reveals specific titin fragments as biomarkers of Duchenne muscular dystrophy.
Rouillon J; Zocevic A; Leger T; Garcia C; Camadro JM; Udd B; Wong B; Servais L; Voit T; Svinartchouk F
Neuromuscul Disord; 2014 Jul; 24(7):563-73. PubMed ID: 24813925
[TBL] [Abstract][Full Text] [Related]
5. Xanthine oxidase is hyper-active in Duchenne muscular dystrophy.
Lindsay A; McCourt PM; Karachunski P; Lowe DA; Ervasti JM
Free Radic Biol Med; 2018 Dec; 129():364-371. PubMed ID: 30312761
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Protective Effect of Human Dystrophin Expressing Chimeric (DEC) Cell Therapy on Amelioration of Function of Cardiac, Respiratory and Skeletal Muscles in Duchenne Muscular Dystrophy.
Siemionow M; Langa P; Brodowska S; Kozlowska K; Zalants K; Budzynska K; Heydemann A
Stem Cell Rev Rep; 2022 Dec; 18(8):2872-2892. PubMed ID: 35590083
[TBL] [Abstract][Full Text] [Related]
7. Electrical impedance myography detects dystrophin-related muscle changes in mdx mice.
Hiyoshi T; Zhao F; Baba R; Hirakawa T; Kuboki R; Suzuki K; Tomimatsu Y; O'Donnell P; Han S; Zach N; Nakashima M
Skelet Muscle; 2023 Nov; 13(1):19. PubMed ID: 37980539
[TBL] [Abstract][Full Text] [Related]
8. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
[TBL] [Abstract][Full Text] [Related]
9. Live-imaging of revertant and therapeutically restored dystrophin in the Dmd
Petkova MV; Stantzou A; Morin A; Petrova O; Morales-Gonzalez S; Seifert F; Bellec-Dyevre J; Manoliu T; Goyenvalle A; Garcia L; Richard I; Laplace-Builhé C; Schuelke M; Amthor H
Neuropathol Appl Neurobiol; 2020 Oct; 46(6):602-614. PubMed ID: 32573804
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological Inhibition of PKCθ Counteracts Muscle Disease in a Mouse Model of Duchenne Muscular Dystrophy.
Marrocco V; Fiore P; Benedetti A; Pisu S; Rizzuto E; Musarò A; Madaro L; Lozanoska-Ochser B; Bouché M
EBioMedicine; 2017 Feb; 16():150-161. PubMed ID: 28089792
[TBL] [Abstract][Full Text] [Related]
11. Antisense Oligonucleotide Treatment in a Humanized Mouse Model of Duchenne Muscular Dystrophy and Highly Sensitive Detection of Dystrophin Using Western Blotting.
Maruyama R; Yokota T
Methods Mol Biol; 2021; 2224():203-214. PubMed ID: 33606217
[TBL] [Abstract][Full Text] [Related]
12. Lentiviral Micro-dystrophin Gene Treatment into Late-stage mdx Mice for Duchenne Muscular Dystrophy Disease.
Eren SA; Tastan C; Karadeniz KB; Turan RD; Cakirsoy D; Kancagi DD; Yilmaz SU; Oztatlici M; Oztatlici H; Ozer S; Tumentemur G; Baykal AT; Ovali E
Curr Gene Ther; 2023; 23(4):304-315. PubMed ID: 37032509
[TBL] [Abstract][Full Text] [Related]
13. Human dystrophin expressing chimeric (DEC) cell therapy ameliorates cardiac, respiratory, and skeletal muscle's function in Duchenne muscular dystrophy.
Siemionow M; Langa P; Harasymczuk M; Cwykiel J; Sielewicz M; Smieszek J; Heydemann A
Stem Cells Transl Med; 2021 Oct; 10(10):1406-1418. PubMed ID: 34291884
[TBL] [Abstract][Full Text] [Related]
14. Investigating the role of dystrophin isoform deficiency in motor function in Duchenne muscular dystrophy.
Chesshyre M; Ridout D; Hashimoto Y; Ookubo Y; Torelli S; Maresh K; Ricotti V; Abbott L; Gupta VA; Main M; Ferrari G; Kowala A; Lin YY; Tedesco FS; Scoto M; Baranello G; Manzur A; Aoki Y; Muntoni F
J Cachexia Sarcopenia Muscle; 2022 Apr; 13(2):1360-1372. PubMed ID: 35083887
[TBL] [Abstract][Full Text] [Related]
15. Mdx mice inducibly expressing dystrophin provide insights into the potential of gene therapy for duchenne muscular dystrophy.
Ahmad A; Brinson M; Hodges BL; Chamberlain JS; Amalfitano A
Hum Mol Genet; 2000 Oct; 9(17):2507-15. PubMed ID: 11030755
[TBL] [Abstract][Full Text] [Related]
16. Discovery of serum protein biomarkers in the mdx mouse model and cross-species comparison to Duchenne muscular dystrophy patients.
Hathout Y; Marathi RL; Rayavarapu S; Zhang A; Brown KJ; Seol H; Gordish-Dressman H; Cirak S; Bello L; Nagaraju K; Partridge T; Hoffman EP; Takeda S; Mah JK; Henricson E; McDonald C
Hum Mol Genet; 2014 Dec; 23(24):6458-69. PubMed ID: 25027324
[TBL] [Abstract][Full Text] [Related]
17. Social stress is lethal in the mdx model of Duchenne muscular dystrophy.
Razzoli M; Lindsay A; Law ML; Chamberlain CM; Southern WM; Berg M; Osborn J; Engeland WC; Metzger JM; Ervasti JM; Bartolomucci A
EBioMedicine; 2020 May; 55():102700. PubMed ID: 32192914
[TBL] [Abstract][Full Text] [Related]
18. N-terminal titin fragment: a non-invasive, pharmacodynamic biomarker for microdystrophin efficacy.
Boehler JF; Brown KJ; Ricotti V; Morris CA
Skelet Muscle; 2024 Jan; 14(1):2. PubMed ID: 38229112
[TBL] [Abstract][Full Text] [Related]
19. Exon Skipping Therapy Using Phosphorodiamidate Morpholino Oligomers in the mdx52 Mouse Model of Duchenne Muscular Dystrophy.
Miyatake S; Mizobe Y; Takizawa H; Hara Y; Yokota T; Takeda S; Aoki Y
Methods Mol Biol; 2018; 1687():123-141. PubMed ID: 29067660
[TBL] [Abstract][Full Text] [Related]
20. Embryonic myosin is a regeneration marker to monitor utrophin-based therapies for DMD.
Guiraud S; Edwards B; Squire SE; Moir L; Berg A; Babbs A; Ramadan N; Wood MJ; Davies KE
Hum Mol Genet; 2019 Jan; 28(2):307-319. PubMed ID: 30304405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]